For latest information on South African COVID-19 Resource Portal go to sacoronavirus.co.za
Toggle Bar

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.

Francis, J., Zvada, S.P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., Dawson, R., Dorman, S., Gupte, N., Wiesner, L. and Jindani, A., 2019. Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis. Antimicrobial Agents and Chemotherapy, pp.AAC-01964. [Epub ahead of print]